NCT05221008View on ClinicalTrials.gov

A Trial of SHR6508 in Secondary Hyperparathyroidism

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

July 7, 2023

Study Completion Date

August 2, 2023

Conditions
Secondary Hyperparathyroidism
Interventions
DRUG

SHR6508；Placebo

Group A:SHR6508 low dose

DRUG

SHR6508；Placebo

Group B:SHR6508 medium dose

DRUG

SHR6508；Placebo

Group C:SHR6508 high dose

DRUG

SHR6508；Placebo

Group D:SHR6508 high dose(single dose)

Trial Locations (1)

Unknown

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY